Aduhelm is FDA Approved for Alzheimer's, But Does it Work?

The video discusses the FDA's approval of a new Alzheimer's drug, highlighting the controversy surrounding its efficacy and cost. While the drug reduces brain plaques, its impact on disease progression is unclear. The approval has sparked debate among experts, with concerns about side effects and financial burden on Medicare. The FDA requires further trials, and a federal investigation into the approval process is underway.

What are the implications of the controversy surrounding the relationship between amyloid plaques and Alzheimer's disease?

What are the potential financial burdens on patients and taxpayers due to the high cost of the drug?

What is the significance of the FDA requiring a third trial for the drug agile helm?